Compare AstraZeneca plc (AZN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Tesla, Inc. — how do they compare? AstraZeneca plc trades at $168.48 (market cap $253.13B), while Tesla, Inc. trades at $398.39 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 5.9× AstraZeneca plc's market cap, and AstraZeneca plc pays a 1.92% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| AZN | TSLA | |
|---|---|---|
Market Cap | $253.13B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $489.88 |
52-Week Low | $137.44 | $302.63 |
Enterprise Value | $279.37B | $1.46T |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Tesla (TSLA) trades at $401.71, up 1.76% on the day, but remains in a bearish technical trend with resistance near $408. The stock shows mixed fundamentals with a high P/E of 363.47 and declining profit margins (3.95% net income margin in 2025), though recent Q1 2026 EPS beat expectations. Cash flow improved to $579M net in 2025, but revenue growth has stalled near $95B. Positive developments include European regulatory approval for self-driving software and a potential cheaper EV launch, per The Motley Fool (April 11, 2026).
Outlook is cautious due to valuation concerns and competitive pressures, but long-term optimism hinges on AI and autonomy breakthroughs. Risks include execution challenges in robotics/energy pivots and volatile sentiment. Analysts are divided with a $409.26 consensus target, suggesting limited upside. Investors should weigh high growth expectations against margin compression and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
